What does OIBD stand for?

Opioid-Induced Bowel Dysfunction

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Option Internationale du Baccalauréat (French educational degree program) Osobni Indentifikacijski Broj (Croatia) Österreichisches Institut für Bautechnik (Austria) Ozellestirme Idaresi Baskanligi Oklahoma Indian Bar Association (Oklahoma City, OK) Operating Income Before Amortization Ottawa Insurance Brokers Association (est. 2006; Canada) Oxford International Biomedical Centre (Oxford, UK) Office of International Business Development (Pennsylvania) Operating Income Before Depreciation (finance)		Operating Income Before Depreciation & Amortization Offizier Im Besonderen Einsatz (German: Officers in Particular Use; German state security staff) Oxford International Business English Certificate (University of Oxford; UK) Oklahoma International Bluegrass Festival Operator Initiated Built in Test Operating Income Before Interest, Taxes, Depreciation and Amortization Opportunity International Bank of Malawi (bank focuses on economically needy; Lilongwe, Malawi) Office of International Business Programs (Tennessee State University College of Business; Nashville, TN) Original Image Bit Processing Organisation Internationale de Biophysique Pure et Appliquée (French: International Organization for Pure and Applied Biophysics)

Samples in periodicals archive:

Opioid-induced bowel dysfunction (OBD) is thought to result primarily from action of opioids upon the mu receptor in the colonic myenteric plexus, which results in lack of contractility of the longitudinal muscle fibers, and hence a loss of peristalsis.

Journal Review: Constipation caused by opioids treated with MTX

today announced top-line results from two identically-designed phase 3 clinical trials of lubiprostone (24 mcg, twice daily) for the management of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain.

Takeda and Sucampo Report Top-Line Results of Two Phase 3 Trials of ...

as well as ADL7445, a proprietary, mu-opioid receptor antagonist that is expected to begin Phase 1 testing in 2009 for opioid-induced bowel dysfunction.

Adolor Corporation Announces Staff Reductions and Restructuring

We were able to meet our goals of successfully completing our initial public offering (IPO), internalizing our contract sales force, and enrolling our first patients in two clinical trials - Phase III pivotal studies of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) and a multi-center Phase II dose-finding trial of cobiprostone (SPI-8811), for the prevention of ulcers and other gastrointestinal injuries in arthritis patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).

Sucampo Pharmaceuticals Reports Financial Results for the Third ...

These additional data include the final results of Study 101684, an extension of the Phase 2b Study 008 of alvimopan in cancer pain patients with opioid-induced bowel dysfunction (OBD), further analysis of results from Study 014 and the final study reports from the two-year carcinogenicity studies in rats and mice, which were conducted to support the OBD indication.

GSK and Adolor Update Alvimopan (Entereg/Entrareg(R)) Development ...

5 mg twice daily in patients taking opioids for chronic non-cancer pain and experiencing opioid-induced bowel dysfunction (OBD).

GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study ...

The FDA has requested 12-month safety data, including analysis of serious cardiovascular events, from study 767905/014, an ongoing safety study in opioid-induced bowel dysfunction (OBD).

FDA Issues Approvable Letter for Entereg(R) (alvimopan) for POI

GlaxoSmithKline (LSE:GSK)(NYSE:GSK) and Adolor Corporation (Nasdaq:ADLR) today announced top-line results from two identically designed Phase 3 registration studies (012 and 013) of alvimopan (Entereg(R)/Entrareg(R)) for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic non-cancer pain.

GlaxoSmithKline and Adolor Report Top-Line Results From Phase 3 ...